Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Verastem ( (VSTM) ) is now available.
On January 8, 2026, Verastem, Inc. updated and posted its corporate presentation, highlighting its strategy around AVMAPKI FAKZYNJA CO-PACK, which is approved for adult patients with KRAS mutant-type recurrent low-grade serous ovarian cancer, and outlining plans to potentially expand its indication beyond KRAS mutation status based on ongoing and planned trials such as RAMP 201 and RAMP 301. The presentation also detailed the company’s broader clinical and partnership pipeline, including a Phase 1/2a study with GenFleet for VS-7375, while emphasizing significant development, regulatory, commercialization, financing, intellectual property, competitive, and operational risks that could materially affect clinical timelines, market uptake, and Verastem’s ability to sustain its oncology business and meet its strategic objectives.
The most recent analyst rating on (VSTM) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Verastem stock, see the VSTM Stock Forecast page.
Spark’s Take on VSTM Stock
According to Spark, TipRanks’ AI Analyst, VSTM is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses, heavy cash burn, and negative equity with higher debt). Technicals also reflect recent downside momentum (below key moving averages and negative MACD). These are partly offset by a positive earnings-call outlook driven by strong initial commercial launch metrics, pipeline progress, and cash runway into 2H 2026.
To see Spark’s full report on VSTM stock, click here.
More about Verastem
Verastem, Inc., which operates as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing novel therapies targeting RAS/MAPK pathway-driven cancers. Its lead assets include AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) for low-grade serous ovarian cancer and additional product candidates and programs being advanced through internal development and collaborations, including with GenFleet Therapeutics in China.
Average Trading Volume: 2,335,850
Technical Sentiment Signal: Hold
Current Market Cap: $518.2M
Learn more about VSTM stock on TipRanks’ Stock Analysis page.